Last reviewed · How we verify

Nebulized Magnesium Sulfate

Hospital General Naval de Alta Especialidad - Escuela Medico Naval · FDA-approved active Small molecule Quality 5/100

Nebulized Magnesium Sulfate, marketed by Hospital General Naval de Alta Especialidad - Escuela Medico Naval, holds a unique position in the respiratory therapy segment. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the lack of clear revenue data and key trial results, which may limit investor confidence and market adoption.

At a glance

Generic nameNebulized Magnesium Sulfate
Also known asMgSO4, Inhaled magnesium sulfate, Nebulized MgSO4, magnesium heptahydrate
SponsorHospital General Naval de Alta Especialidad - Escuela Medico Naval
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: